Future Directions in Eosinophilic Esophagitis

Ikuo Hirano

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Eosinophilic esophagitis advances parallel the increased prevalence. Developments include refining the diagnostic criteria, identifying risk factors, appreciating the contribution of inflammatory pathways, recognizing the importance of subepithelial remodeling, validating trial endpoints, defining a role for biological therapies, and optimizing dietary therapy. Endoscopic outcomes have emerged as endpoints in trials of novel therapeutics. Expanding efforts seek to develop less-invasive methods to assess disease activity thereby reducing the burden of repeated endoscopic procedures during elimination diets. The functional lumen imaging probe is now identified as a determinant of complications with potential utility as a therapeutic endpoint.

Original languageEnglish (US)
Pages (from-to)111-122
Number of pages12
JournalGastrointestinal Endoscopy Clinics of North America
Volume28
Issue number1
DOIs
StatePublished - Jan 2018

Funding

Disclosures: Ikuo Hirano Consulting: Adare, Celgene, Regeneron, Shire. Research funding: Celgene, Regeneron, Shire.

Keywords

  • Dysphagia
  • Eosinophilic esophagitis
  • Esophageal stricture
  • Esophagitis
  • Food allergy
  • Gastroesophageal reflux disease

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Future Directions in Eosinophilic Esophagitis'. Together they form a unique fingerprint.

Cite this